Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

ML327

Catalog No: tcsc0023395

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1883510-31-3

Formula:
$C_{19}H_{18}N_4O_4$

Pathway:
Apoptosis

Target:
c-Myc

Purity / Grade:
>98%

Solubility:
DMSO : 32 mg/mL (87.34 mM; Need ultrasonic and warming)

Observed Molecular Weight:
366.37

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

ML327 is a blocker of **MYC** which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).

IC50 & Target: MYC[1]

In Vitro: Treatment with ML327 induces an elongated morphology in neuroblastoma cells. BE(2)-C cells treated with ML327 demonstrates G1 cell cycle arrest with a concordant decrease in S phase population, and a significant increase in the sub G0 population. ML327 induces the expression of *CDH1* in all seven of the neuroblastoma cell lines with a 50 to 1,400-fold induction of *CDH1* mRNA expression. ML327 blocks the expression of MYC family of oncogenic transcription factors in all tested neuroblastoma cell lines. Immunoblotting time course demonstrates early repression of N-MYC expression within 2 h of treatment with ML327 (10 μM). p53 levels are also suppressed by treatment with ML327. ML327-pretreated cells demonstrates reduced proliferative potential in both tetrazolium-based (p[1]. ML327 reduces SW620inv cell invasion through Matrigel by ~60% and reduces H520 cell invasion by ~30% in these *in vitro* assays. ML327 partially restores E-cadherin expression at the plasma membrane in NMuMG cells induced to undergo Epithelial-to-Mesenchymal Transition (EMT) by TGF-β1 treatment[2].

In Vivo: ML327 treatment significantly reduces tumor volume by three-fold over the two-week treatment period (p=0.02). Tumor explant weights are approximately three-fold smaller in the ML327-treated mice (p=0.01). Mice treated with ML327 lost 12% more body weight than vehicle treated mice. ML327 treatment results in a two-fold decrease in *MYCN* expression, confirming that ML327 inhibits xenograft *MYCN* expression (p=0.0035)[1].